60 Degrees Pharmaceuticals, Inc. SXTP 深 沪
已收盘 09-12 16:00:00 美东时间
1.40
-0.020
-1.41%
华盛通- 最 高1.42
- 今 开1.42
- 成交量 3.17万股
- 最 低 1.37
- 昨 收 1.42
- 总市值 437.16万
- 52周最高 12.45
- 市盈率 静 --
- 换手率 1.01%
- 52周最低 1.215
- 委 比 -99.75%
- 总股本 312.26万
- 历史最高 519.00
- 量 比 0.68
- 振 幅 3.52%
- 历史最低 1.37
- 每 手 1
- 风险率 1.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多60 Degrees Pharmaceuticals Enters New Sales Agreement
The latest update is out from 60 Degrees Pharmaceuticals, Inc. ( ($SXTP) ). On ...
09-06 04:50
Alphabet To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a comple...
09-03 20:25
Ascendiant Capital Maintains Buy on 60 Degrees, Lowers Price Target to $3
Ascendiant Capital analyst Lucas Ward maintains 60 Degrees (NASDAQ:SXTP) with a Buy and lowers the price target from $7 to $3.
09-03 18:45
60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) announced its participation in the 27th Annual Global Investment Conference hosted by H.C. Wainwright (HCW) from September 8-10, 2025, at the Lotte New York Palace Hotel. Dr. Geoff Dow, CEO, will present live on September 10, 2:30 ET, with management available for 1x1 meetings. The presentation will be webcast live and available for replay for 90 days. For more information, visit the investor...
08-21 12:31
60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
60 Degrees Pharmaceuticals has signed a clinical trial agreement with Mount Sinai's Icahn School of Medicine to evaluate ARAKODA (tafenoquine) in treating chronic babesiosis, a debilitating illness with no FDA-approved treatment. The Phase II study will measure fatigue resolution in patients with at least six months of symptoms and assess the drug's safety and efficacy over 90 days. Enrollment is expected to commence in Q4 2025 and complete by Q2...
08-19 12:54
60 Degrees Q2 EPS $(1.25) Misses $(0.96) Estimate, Sales $101.000K Miss $301.000K Estimate
60 Degrees (NASDAQ:SXTP) reported quarterly losses of $(1.25) per share which missed the analyst consensus estimate of $(0.96) by 30.21 percent. This is a 70.45 percent increase over losses of $(4.23) per share from the
08-14 04:19
60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results
60 Degrees Pharmaceuticals第二季度净产品收入同比下降19%，但因采用现金支付分销模式提高了盈利能力。公司拥有197万美元现金储备，预计可维持至2026年3月31日。尽管供应链中断影响了ARA-KODA 16盒装销量，但引入新的8盒装瓶和FDA批准的KODATEF 16盒装进口缓解了部分影响。公司还完成了几项商业研究，估计 babesiosis 的年度发病率在25,000至380,000例之间，预计未来10年内 ARK-O-D 的市场规模可能达到11亿美元。
08-13 20:14
60 Degrees Pharmaceuticals Secures $5M in Recent Offering
60 Degrees Pharmaceuticals, Inc. ( ($SXTP) ) has provided an announcement. On J...
07-19 05:17
60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria
60 Degrees Pharmaceuticals, Inc.与 Tulane University合作，启动研究评估tafenoquine对Borrelia（莱姆病）、Bartonella及Babesia（共同称为“3B”病原体）的活性。研究旨在探索tafenoquine治疗由这些病原体引发的共感染潜力。目前，tafenoquine获批用于疟疾预防，但尚未证明对 babesiosis 或Borrelia、Bartonella有效，也未获准用于这些适应症。
07-17 12:01
Market-Moving News for July 15th
TTD: 16% | The Trade Desk Will Replace Ansys In The S&P 500 Effective Prior To The Opening Of Trading On Friday, July 18 XAGE: 106% | Longevity Health Executes Definitive Merger Agreement With True
07-15 19:15
